Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II

Purpose: A phase II study that used combination che-motherapy with carboplatin (CBDCA) and etoposide (VP 16) (CE) was performed on patients with recurrent malig-nant glioma to investigate tumor control and toxicity. Patients and Methods: Thirty-eight patients were treat-ed with CBDCA 300 mg/m2 on days 1 to 3 and VP 16 100 mg/m 2 on days 1 to 5. A minimum of three courses were required unless the patient had a rapid progression of disease (PD). Courses were repeated every 4 weeks